Our objective is to explore whether the prolongation to the BUB1 timer can be used to sensitize mesotheliomas to prevailing combinations of DNA-damaging and anti-mitotic therapies. For this purpose, we will first compare the properties of the BUB1 timer in engineered mesothelial and mesothelioma cell lines. We will proceed to explore BUB1-timer prolonging strategies using temperuture-based protocols or inhibators of timer silencing identified ...
Translational genomics of malignant pleural mesothelioma. University of Antwerp
Investigation of combined immune checkpoint blockade in malignant pleural mesothelioma. University of Antwerp
Improving frontline treatment for malignant pleural mesothelioma with concomitant platinum/pemetrexed-based chemotherapy and Wilms' tumor protein 1 (WT1)-targeted dendritic cell immunotherapy. University of Antwerp
First-line chemoimmunotherapy using Wilms' tumor protein 1 (WT1)-targeted dendritic cell vaccinations for resectable malignant pleural mesothelioma. University of Antwerp
The role of blood protein biomarkers in the management of malignant pleural mesothelioma Ghent University
This research work focused on malignant pleural mesothelioma, a fatal asbestos-related malignancy. The resulting doctoral thesis describes the role of three novel blood protein biomarkers, soluble mesothelin, megakaryocyte potentiating factor, and osteopontin, in different fields of mesothelioma management, including diagnosis, screening, prognosis and monitoring response to therapy.